UNH - 3 Reasons Not To Buy After 'Beat & Raise'

United Health (UNH) attracts value investors after Q3 earnings beat, but rising costs and margin pressures pose risks.

Is This Defensive Giant a Good Stock to Buy in a Volatile Market?

Defensive blue-chip stock UnitedHealth is on a credible path back to double-digit growth next year, but is UNH a buy right ...

Critical Mass With Law.com's Amanda Bronstad: Utah AG Fires Motley Rice From Opioid Lit., Video Privacy Suit Moves Forward Against LinkedIn

In his opening statement, Nelson Mullins’ Michael A. Brown, representing the company, said evidence would show the talc did ...

Sprouts files lawsuit against insulin manufacturers, PBMs

The specialty grocer, which spends millions each year on insulin for employees, accused the companies of profiting from ...

UnitedHealth May Reach Trough Profit Levels in 2025, Before Improving in the Long Run

UnitedHealth Group operates a top-tier health insurer (UnitedHealthcare), pharmacy benefit manager (Optum Rx), provider (Optum Health), and health analytics franchise (Optum Insight). Historically, ...

UnitedHealth: Nothing Is Over

UnitedHealth Group delivered Q3 revenue of $113.2 billion, up 12.3% year-over-year, slightly ahead of consensus estimates.

Cigna Will End Drug Rebates in Many Private Health Plans (3)

Cigna will eliminate prescription drug rebates in many of its commercial health plans in 2027, upending a practice that’s ...
Healthcare Innovation

Cigna to End Drug Rebates in Many Private Health Plans in 2027

Cigna Group will stop offering prescription drug rebates in many of its commercial health plans starting in 2027, Bloomberg’s ...

How Cigna’s rebate-free plan could reshape US drug pricing

Cigna will remove drug rebates from 2027, replacing them with upfront discounts that could change how Americans pay for ...